BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, July 24, 2026
Breaking News: Single-cell transcriptome study points to new drug targets for preeclampsiaBreaking News: Single-cell transcriptome study points to new drug targets for preeclampsiaBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Cancer

C4x Discovery's MALT1 inhibitor lead series shows reduced UGT1A1 inhibition at clinically meaningful doses

June 2, 2023
C4x Discovery Holdings plc has announced further progress in its MALT1 inhibitor program for cancer. Building on anti-cancer activity in a preclinical xenograft study, the company completed a preclinical study demonstrating its MALT1 lead compounds were free of UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) liability shown by competitor chemistries. The program is continuing to identify a shortlist of preclinical candidates for further development, and a partnering program has been initiated.
Read More
Neon brain
Neurology/Psychiatric

Identification and development of a PET radiotracer for imaging α-synucleinopathies

June 2, 2023
α-Synucleinopathies constitute a set of neurological disorders including Parkinson’s disease (PD), dementia with Lewy bodies, multiple systems atrophy (MSA), and other rare disorders. The development of positron emission tomography (PET) tracers for imaging α-synuclein aggregates is essential for performing efficient and accurate diagnosis, tracking disease progression and monitoring efficacy of potential therapies.
Read More
Cancer

Impact Therapeutics and Eikon collaborate to develop and commercialize PARP1 selective inhibitors

June 2, 2023
Impact Therapeutics Inc. and Eikon Therapeutics...
Read More
Tumor necrosis factor (TNF), a cytokine involved in inflammation processes
Immuno-oncology

Bioinvent's anti-TNFR2 antibody BI-1910 cleared to enter clinic

June 2, 2023
Bioinvent International AB has received IND...
Read More
Lungs
Respiratory

ROCK2 inhibitor GNS-3595 reduces IPF progression in preclinical models

June 2, 2023
Idiopathic pulmonary fibrosis (IPF) is a chronic...
Read More
3D rendering of serotonin molecular structure
Neurology/Psychiatric

New serotonin transporter inhibitors with anxiolytic and antidepressant effects

June 2, 2023
Two newly identified compounds that inhibit the...
Read More
Cancer

Macrophage senescence promotes lung cancer progression

June 2, 2023
By Mar de Miguel
With age, senescent cells become detrimental to tissues. Mayo Clinic scientists have observed this phenomenon in the lung alveoli, where senescent macrophages accumulated in aging tissue and in early stages of non-small-cell lung cancer (NSCLC) driven by the Kras oncogene. “We found that the macrophages were present in the earliest stages of the disease. Strategies targeting these cells for elimination or preventing their accumulation would be worthwhile to test in other conditions (assuming we find they occur),” Darren Baker, a Mayo Clinic senescent cell biologist and senior author of the study, told BioWorld.
Read More
Stained image of triple-negative breast cancer showing molecular heterogeneity
Cancer

Intratumor heterogeneity mapped in large study

June 2, 2023
By Helen Albert
A study of more than a thousand tumor samples, led by the Weizmann Institute of Science in Israel, gives valuable insight into the different gene expression patterns seen in different cancers. The new findings could help address challenges associated with targeting many types of tumors, which are hard to treat in large part due to the variable nature of their cells and gene expression patterns, by helping to create better targeted therapeutics.
Read More

Other news to note for June 1, 2023

June 1, 2023
Additional early-stage research and drug discovery news in brief, from: Omega Therapeutics.
Read More
Musculoskeletal

Aria Pharmaceuticals discovers new CCR2 modulators for SLE and lupus nephritis

June 1, 2023
Aria Pharmaceuticals Inc. has described C-C chemokine receptor type 2 (CCR2; MCP-1-R) modulators reported to be useful for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
Read More
Previous 1 2 … 1128 1129 1130 1131 1132 1133 1134 1135 1136 … 18135 18136 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 23, 2026.
  • Red CAR T cell on blue blackground

    To viral or not to viral: In vivo CAR T debates delivery tech

    BioWorld
    The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 21, 2026
  • Tree in the shape of human head losing leaves

    KBN-2201 reverses key features of Alzheimer’s in mice

    BioWorld Science
    Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.
  • Click chemistry drug bound to pancreatic cancer cells from mice

    In vivo click ADCs could address tumor heterogeneity

    BioWorld
    Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing